BET Proteins: Investigating BRDT As a Potential Target for Male Contraception

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2020 Feb 6

PMID 32019712

Citations 5

Authors

Andrea Wisniewski

Gunda I Georg

Affiliations

Soon will be listed here.

Abstract

While many contraception options are available for women, birth control methods for men are limited to condoms and vasectomy. Past research into male contraceptives has focused on hormonal options but the associated side effects have thus far precluded this method from reaching the market. Non-hormonal male contraceptives and vas occlusion have also been explored, but to date no method has progressed past clinical testing. Recent interest in epigenetic research has unveiled a new potential non-hormonal male contraceptive target: the testis-specific bromodomain BRDT. Potent inhibitors for bromodomain-containing proteins are described in the literature, but a BRDT-specific compound has yet to be designed, prepared and tested. The high similarity between bromodomain proteins of the BET family makes development of selective and specific inhibitors both difficult and necessary. Selective inhibition of BRDT by a small molecule is an exciting new target in the search for a new non-hormonal male contraceptive.

Citing Articles

Male contraception: narrative review of ongoing research.

Louwagie E, Quinn G, Pond K, Hansen K Basic Clin Androl. 2023; 33(1):30.

PMID: 37940863 PMC: 10634021. DOI: 10.1186/s12610-023-00204-z.

Non-Hormonal Contraception.

Howard S, Benhabbour S J Clin Med. 2023; 12(14).

PMID: 37510905 PMC: 10381146. DOI: 10.3390/jcm12144791.

Emerging concepts in male contraception: a narrative review of novel, hormonal and non-hormonal options.

Service C, Puri D, Hsieh T, Patel D Ther Adv Reprod Health. 2023; 17:26334941221138323.

PMID: 36909934 PMC: 9996746. DOI: 10.1177/26334941221138323.

The novel BRDT inhibitor NHWD870 shows potential as a male contraceptive in mice.

Wu S, Li X, Shang L, Wu L, Li T, Li P Acta Biochim Biophys Sin (Shanghai). 2022; 54(12):1789-1800.

PMID: 36239350 PMC: 10157631. DOI: 10.3724/abbs.2022135.

Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.

Long J, Lee M, Blithe D J Clin Endocrinol Metab. 2021; 106(6):e2381-e2392.

PMID: 33481994 PMC: 8344836. DOI: 10.1210/clinem/dgab034.

References

Baralle F, Giudice J . Alternative splicing as a regulator of development and tissue identity. Nat Rev Mol Cell Biol. 2017; 18(7):437-451. PMC: 6839889. DOI: 10.1038/nrm.2017.27. View

Schneekloth A, Pucheault M, Tae H, Crews C . Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics. Bioorg Med Chem Lett. 2008; 18(22):5904-8. PMC: 3175619. DOI: 10.1016/j.bmcl.2008.07.114. View

Raina K, Lu J, Qian Y, Altieri M, Gordon D, Rossi A . PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016; 113(26):7124-9. PMC: 4932933. DOI: 10.1073/pnas.1521738113. View

Choudhary C, Kumar C, Gnad F, Nielsen M, Rehman M, Walther T . Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009; 325(5942):834-40. DOI: 10.1126/science.1175371. View

Gacias M, Gerona-Navarro G, Plotnikov A, Zhang G, Zeng L, Kaur J . Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression. Chem Biol. 2014; 21(7):841-854. PMC: 4104156. DOI: 10.1016/j.chembiol.2014.05.009. View

Gadd M, Testa A, Lucas X, Chan K, Chen W, Lamont D . Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017; 13(5):514-521. PMC: 5392356. DOI: 10.1038/nchembio.2329. View

Sabatini R, Cagiano R . Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception. 2006; 74(3):220-3. DOI: 10.1016/j.contraception.2006.03.022. View

Winter G, Buckley D, Paulk J, Roberts J, Souza A, Dhe-Paganon S . DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015; 348(6241):1376-81. PMC: 4937790. DOI: 10.1126/science.aab1433. View

Belkina A, Denis G . BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012; 12(7):465-77. PMC: 3934568. DOI: 10.1038/nrc3256. View

10.

Vazquez R, Riveiro M, Astorgues-Xerri L, Odore E, Rezai K, Erba E . The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. Oncotarget. 2016; 8(5):7598-7613. PMC: 5352346. DOI: 10.18632/oncotarget.13814. View

11.

Pande V . Understanding the Complexity of Epigenetic Target Space. J Med Chem. 2016; 59(4):1299-307. DOI: 10.1021/acs.jmedchem.5b01507. View

12.

Garcia-Gutierrez P, Mundi M, Garcia-Dominguez M . Association of bromodomain BET proteins with chromatin requires dimerization through the conserved motif B. J Cell Sci. 2012; 125(Pt 15):3671-80. DOI: 10.1242/jcs.105841. View

13.

Tamkun J, Deuring R, Scott M, Kissinger M, Pattatucci A, Kaufman T . brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell. 1992; 68(3):561-72. DOI: 10.1016/0092-8674(92)90191-e. View

14.

Shi J, Cao J, Zhou B . Twist-BRD4 complex: potential drug target for basal-like breast cancer. Curr Pharm Des. 2014; 21(10):1256-61. PMC: 5644350. DOI: 10.2174/1381612821666141211153853. View

15.

Shadrick W, Slavish P, Chai S, Waddell B, Connelly M, Low J . Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem. 2017; 26(1):25-36. PMC: 5733700. DOI: 10.1016/j.bmc.2017.10.042. View

16.

Berkovits B, Wolgemuth D . The first bromodomain of the testis-specific double bromodomain protein Brdt is required for chromocenter organization that is modulated by genetic background. Dev Biol. 2011; 360(2):358-68. PMC: 3217133. DOI: 10.1016/j.ydbio.2011.10.005. View

17.

Delmore J, Issa G, Lemieux M, Rahl P, Shi J, Jacobs H . BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6):904-17. PMC: 3187920. DOI: 10.1016/j.cell.2011.08.017. View

18.

Ottis P, Crews C . Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy. ACS Chem Biol. 2017; 12(4):892-898. DOI: 10.1021/acschembio.6b01068. View

19.

Owen D, Ornaghi P, Yang J, Lowe N, Evans P, Ballario P . The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 2000; 19(22):6141-9. PMC: 305837. DOI: 10.1093/emboj/19.22.6141. View

20.

Churcher I . Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?. J Med Chem. 2017; 61(2):444-452. DOI: 10.1021/acs.jmedchem.7b01272. View